Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2025)

Historic EBT Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 10.69%.

  • Tarsus Pharmaceuticals' EBT Margin rose 381300.0% to 10.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.13%, marking a year-over-year increase of 803100.0%. This contributed to the annual value of 63.16% for FY2024, which is 7157300.0% up from last year.
  • Tarsus Pharmaceuticals' EBT Margin amounted to 10.69% in Q3 2025, which was up 381300.0% from 19.67% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBT Margin registered a high of 33.11% during Q2 2021, and its lowest value of 4271.01% during Q4 2021.
  • Its 5-year average for EBT Margin is 765.63%, with a median of 76.64% in 2024.
  • Examining YoY changes over the last 5 years, Tarsus Pharmaceuticals' EBT Margin showed a top increase of 41347500bps in 2022 and a maximum decrease of -37124100bps in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBT Margin (Quarter) stood at 4271.01% in 2021, then surged by 97bps to 136.26% in 2022, then tumbled by -138bps to 324.72% in 2023, then surged by 89bps to 34.76% in 2024, then skyrocketed by 69bps to 10.69% in 2025.
  • Its EBT Margin stands at 10.69% for Q3 2025, versus 19.67% for Q2 2025 and 31.96% for Q1 2025.